1. Agid Y., Ruberg M., Javoy-Agid R., Hirsch E., Raisman-Vozari R., Vyas S., Baucheux B., Michel P., Kastner A., Blanchard B., Damier P., Villares J. and Zhang, P. (1993) Are dopaminergic neurons selectively vulnerable to Parkinson’s disease? In: Narabayashi H., Ngatsu T., Yanagisawa N. and Mizuno, Y. (eds.), Advances in Neurology, Vol. 60, pp 148-164.
2. Barr G. A., Eckenrode T.C. and Murray M. (1987) Normal development and effects of early deafferentation on choline acetyltransferase, substance P and serotonin-like immunoreactivity in the interpeduncular nucleus. Brain Res. 418, 301–313.
3. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K. and Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neural. Sci. 20, 415–455.
4. Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye-binding. Anal. Biochem. 72, 248–254.
5. Carstam R., Brinck C, Fornstedt B., Rorsman H. and Rosengren E. (1990) 5-S-Cysteinyldopac in human urine. Acta Derm. Venereol. (Stockh). 70, 373–377.